The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of CXCR4 expression on tumor and circulating tumor cells (CTCs) as predictive response marker for CXCR4 antagonist LY2510924 in combination with carboplatin-etoposide in extensive-disease small cell lung cancer (ED-SCLC).
 
Ravi Salgia
No Relationships to Disclose
 
R. Waide Weaver
Employment - Florida Cancer Specialists
Honoraria - Celgene; Eisai; Genentech; Millennium
Consulting or Advisory Role - Bayer
Speakers' Bureau - Celgene; Eisai; Genentech; Millennium
 
Michael McCleod
No Relationships to Disclose
 
John R Stille
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Research Funding - Lilly
 
S. Betty Yan
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Research Funding - Lilly
Patents, Royalties, Other Intellectual Property - Lilly
 
Stephanie Roberson
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Oday Hamid
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
John Polzer
Employment - Lilly; Lilly (I)
Stock and Other Ownership Interests - Lilly; Lilly (I)
 
Amy Flynt
Employment - Pharpoint Research
 
Eyas Raddad
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Research Funding - Lilly
Patents, Royalties, Other Intellectual Property - Lilly
 
David R. Spigel
No Relationships to Disclose